JP2025516213A5 - - Google Patents

Info

Publication number
JP2025516213A5
JP2025516213A5 JP2024563509A JP2024563509A JP2025516213A5 JP 2025516213 A5 JP2025516213 A5 JP 2025516213A5 JP 2024563509 A JP2024563509 A JP 2024563509A JP 2024563509 A JP2024563509 A JP 2024563509A JP 2025516213 A5 JP2025516213 A5 JP 2025516213A5
Authority
JP
Japan
Prior art keywords
alkenyl
heterocyclyl
alkynyl
heteroaryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516213A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/091483 external-priority patent/WO2023208173A1/en
Publication of JP2025516213A publication Critical patent/JP2025516213A/ja
Publication of JP2025516213A5 publication Critical patent/JP2025516213A5/ja
Pending legal-status Critical Current

Links

JP2024563509A 2022-04-29 2023-04-28 サイクリン依存性キナーゼ阻害剤としての置換６－（ピリミジン－４－イル）キノリン化合物 Pending JP2025516213A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2022090344 2022-04-29
CNPCT/CN2022/090344 2022-04-29
CNPCT/CN2022/105964 2022-07-15
CN2022105964 2022-07-15
CNPCT/CN2023/085071 2023-03-30
CN2023085071 2023-03-30
PCT/CN2023/091483 WO2023208173A1 (en) 2022-04-29 2023-04-28 Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2025516213A JP2025516213A (ja) 2025-05-27
JP2025516213A5 true JP2025516213A5 (enExample) 2026-05-13

Family

ID=88517887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563509A Pending JP2025516213A (ja) 2022-04-29 2023-04-28 サイクリン依存性キナーゼ阻害剤としての置換６－（ピリミジン－４－イル）キノリン化合物

Country Status (14)

Country Link
US (1) US20240300937A1 (enExample)
EP (1) EP4514791A4 (enExample)
JP (1) JP2025516213A (enExample)
KR (1) KR20250004890A (enExample)
CN (2) CN119095840A (enExample)
AR (1) AR129185A1 (enExample)
AU (1) AU2023260284A1 (enExample)
CA (1) CA3256792A1 (enExample)
CL (1) CL2024003269A1 (enExample)
CO (1) CO2024014595A2 (enExample)
IL (1) IL316556A (enExample)
MX (1) MX2024013266A (enExample)
TW (1) TW202400585A (enExample)
WO (1) WO2023208173A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202513069A (zh) 2023-07-21 2025-04-01 美商冰洲石生物科技公司 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物
EP4791727A1 (en) * 2023-10-11 2026-08-19 Beone Medicines I GmbH Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005076854A2 (en) * 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
EA200870217A1 (ru) * 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
WO2008124085A2 (en) * 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CN118286225A (zh) * 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
WO2022149057A1 (en) * 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Similar Documents

Publication Publication Date Title
TW403748B (en) An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
JP2022532706A5 (enExample)
JP2005320351A5 (enExample)
CN101083993A (zh) 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
BR112020008851A2 (pt) composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP2007531760A5 (enExample)
JP2021512146A (ja) キャップ依存性エンドヌクレアーゼ阻害剤
JP2018534301A5 (enExample)
WO2011116066A1 (en) Derivatives of dimethylcurcumin
ES2935615T3 (es) Azetidina dihidrotienopiridinas sustituidas y su uso como inhibidores de la fosfodiesterasa
CA3187168A1 (en) Compounds, compositions and methods
JP2019521958A (ja) メマンチン化合物及びその調整並びにその使用
WO2014031840A1 (en) Deuterated 4-hydroxybutyric acid analogs
TW202214626A (zh) 雌激素受體調節劑化合物及其用途
JP2025515483A5 (enExample)
WO2022212531A1 (en) Pyridopyrimidinone compounds
JP2005539014A5 (enExample)
JP7751569B2 (ja) 置換フェノールヒドロキシ酸エステルのｎ含有誘導体、製造及び使用
JP2016540786A5 (enExample)
EP4219458A2 (en) Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
RU2009148821A (ru) Производные [1,10]фенантролина для лечения нейродегенеративных или гематологических заболеваний
JP2018510192A5 (enExample)
US20140128469A1 (en) Deuterated n-butyl bumetanide
WO2019105234A1 (zh) 芳香族化合物及其药物组合物和用途
WO2004047725A2 (en) 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors